Introduction: Chronic obstructive pulmonary disease (COPD) with eosinophilic airway
inflammation represents a distinct phenotype that might respond to treatment with inhaled …

Background: The use of fractional exhaled nitric oxide (FeNO) has been proposed for
identifying and monitoring eosinophilic airway inflammation in chronic obstructive …

Introduction During the last decade, many articles have been published, including reviews
on fractional exhaled nitric oxide (FeNO) use and utility in clinical practice and for monitoring …

The value of fractional exhaled nitric oxide (FeNO) in patients with chronic obstructive
pulmonary disease (COPD) remains unclear. We aimed to assess whether FeNO is a more …

Some patients with chronic obstructive pulmonary disease (COPD) have eosinophilic
inflammation which may be evaluated via the measurement of fractional exhaled nitric oxide …

Introduction Measurements of eosinophils in induced sputum and fractional exhaled nitric
oxide (FeNO) are noninvasive biomarkers for assessing airway inflammation phenotypes in …

Background Fractional exhaled nitric oxide (FENO) is a useful and noninvasive biomarker
for eosinophilic airway inflammation, particularly in asthma. However, its utility in chronic …

Chronic obstructive pulmonary disease (COPD) is the most common fixed airflow limitation.
Individuals may present with the features of both asthma and COPD called asthma-COPD …

Fractional exhaled nitric oxide (FENO) may be a pulmonary biomarker in chronic obstructive
pulmonary disease (COPD). In this prospective study, the relationship between FENO and …

Chronic obstructive pulmonary disease (COPD) is a common and progressive disorder
which is characterised by pathological abnormalities driven by chronic airway inflammation …